Showing 1 - 20 results of 21 for search 'V.A. Ionin', query time: 0.05s
Refine Results
-
1
Resistant arterial hypertension: is it really so or have we missed something? by V. A. Ionin
Published 2022-05-01
Article -
2
-
3
Antithrombotic therapy for atrial fibrillation and comorbidities — how to choose the optimal solution? by E V Schlyakhto, E I Baranova, V A Ionin
Published 2022-01-01
Article -
4
-
5
-
6
-
7
Apelin and heart remodeling in patients with abdominal obesity by O. V. Listopad, E. A. Bazhenova, V. A. Ionin, O. D. Belyaeva, E. I. Baranova
Published 2015-06-01
Article -
8
-
9
Molecular mechanisms of the development of atrial fibrillation in patients with type 2 diabetes mellitus: prognostic role of biomarkers of fibrosis and inflammation by V. A. Ionin, E. I. Barashkova, A. M. Ananev, V. A. Pavlova, E. L. Zaslavskaya, E. I. Baranova
Published 2022-11-01
Article -
10
Biomarkers of inflammation, parameters characterizing obesity and cardiac remodeling in patients with atrial fibrillation and metabolic syndrome by V. A. Ionin, E. I. Baraschkova, E. L. Zaslavskaya, S. E. Nifontov, E. A. Bazhenova, O. D. Belyaeva, E. I. Baranova
Published 2021-04-01
Article -
11
-
12
THE ROLE OF TRANSFORMING GROWTH FACTOR BETA-1 AND GALECTIN-3 IN FORMATION OF THE LEFT ATRIUM FIBROSIS IN PATIENTS WITH PAROXYSMAL ATRIAL FIBRILLATION AND METABOLIC SYNDROME by E. L. Zaslavskaya, A. N. Morozov, V. A. Ionin, I. Ma, S. Е. Nifontov, Е. I. Baranova, S. M. Yashin, E. V. Shlyakhto
Published 2018-03-01
Article -
13
-
14
What is the role of profibrogenic and proinflammatory factors in developing atrial fibrillation associated with metabolic syndrome components? by V. A. Ionin, E. I. Barashkova, V. A. Pavlova, G. I. Borisov, K. A. Averchenko, E. L. Zaslavskaya, E. I. Baranova
Published 2021-12-01
Article -
15
-
16
Anticoagulant therapy and components of the metabolic syndrome in patients with atrial fibrillation in real outpatient clinical practice by V. A. Ionin, E. Yu. Petrischeva, D. S. Skuridin, O. I. Bliznyuk, A. A. Ivanova, A. E. Filatova, I. Ma., E. L. Zaslavskaya, E. I. Baranova
Published 2019-04-01
Article -
17
-
18
Molecular mechanisms of left atrial fibrosis development in patients with atrial fibrillation and metabolic syndrome: what biomarkers should be used in clinical practice? by V. A. Ionin, E L Zaslavskaya, E I Barashkova, V A Pavlova, G I Borisov, K A Averchenko, A N Morozov, E I Baranova, E V Schlyachto
Published 2021-08-01
Article -
19
«SGLT2 INHIBITORS: RATIONALE FOR THE USE IN HEART FAILURE», RESOLUTION ON THE RESULTS OF THE PANEL OF EXPERTS WITH INTERNATIONAL PARTICIPATION, ALMATY by S.A. Abzaliyeva, G. A.Junusbekova, I.V. Zhirov, G.K. Zhusupova, K.B. Abzaliyev, M.K. Tundybaeva, R.B. Bazarbekova, A.M. Raisova, A.Yu. Babenko, V.A. Ionin
Published 2022-12-01
Article -
20
С(-344)Т polymorphism of aldosterone synthase gene, risk of metabolic syndrome, and atrial fibrillation risk for inhabitants of the Northwest regions of Russia by I. Ma, A. S. Ulitina, V. A. Ionin, E. L. Zaslavskaya, V. V. Miroshnikova, A. A. Panteleeva, O. D. Belyaeva, E. A. Bazhenova, O A. Berkovich, S. N. Pchelina, E. I. Baranova
Published 2016-06-01
Article